Exelon Patch

Exelon Patch

rivastigmine

Manufacturer:

Novartis

Distributor:

Zuellig
/
Four Star
Concise Prescribing Info
Contents
Rivastigmine
Indications/Uses
Symptomatic treatment of mild to moderately severe Alzheimer's dementia.
Dosage/Direction for Use
Initially 4.6 mg/day. May be increased up to 9.5 mg/day if well tolerated after a min of 4 wk. After a min of 6 mth, the physician may increase the dose to 13.3 mg/24 hr. Apply patch once daily to clean, dry, hairless, intact, healthy skin preferably on the upper or lower back, upper arm or chest.
Contraindications
Hypersensitivity to rivastigmine or other carbamate derivatives. Previous history of application site reactions suggestive of allergic contact dermatitis w/ rivastigmine patch.
Special Precautions
If treatment is interrupted for >3 days, it should be re-initiated w/ 4.6 mg/24 hr. GI disorders may occur at initiation of therapy & shortly after dose increase. Monitor patient's wt during therapy. Sick sinus syndrome, conduction defects (SA & AV block), active gastric or duodenal ulcers or patient predisposed to these conditions; predisposed to urinary obstruction & seizures; history of asthma or obstructive pulmonary disease. Discontinue if allergic contact dermatitis occur. May exacerbate or induce extrapyramidal symptoms. Avoid contact w/ the eyes. Patient <50 kg body wt. Hepatic & renal impairment. May impair ability to drive or operate machinery. Pregnancy & lactation. Ped patient.
Adverse Reactions
Application site reactions (erythema, pruritus, oedema, dermatitis, irritation), asthenic conditions (eg, fatigue, asthenia), pyrexia, decreased wt; headache, syncope, dizziness, nausea, vomiting, diarrhoea, dyspepsia, abdominal pain; UTI; anorexia, decreased appetite; anxiety, depression, delirium, agitation; rash; urinary incontinence.
Drug Interactions
Extra-pyramidal effect w/ metoclopramide. Additive effect w/ anticholinergic drugs (eg, oxybutynin, tolterodine). Exaggerated effects of succinylcholine-type muscle relaxants during anaesth. Additive effect leading to bradycardia w/ β-blocker. Do not give concomitantly w/ other cholinomimetic substances. Inhibits the butyrylcholinesterase-mediated metabolism of other substances.
MIMS Class
Neurodegenerative Disease Drugs
ATC Classification
N06DA03 - rivastigmine ; Belongs to the class of anticholinesterases. Used in the management of dementia.
Presentation/Packing
Form
Exelon Patch dermal patch 9.5 mg/24 hr
Packing/Price
30 × 1's
Form
Exelon Patch transdermal patch 13.3 mg/24 hr
Packing/Price
30's
Form
Exelon Patch transdermal patch 4.6 mg/24 hr
Packing/Price
30 × 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in